Small molecule inhibitors of protein-protein interactions
The development of orally bioavailable small molecule drugs targeting protein-protein interactions (PPIs) has been challenging1. Unlike conventional targets, PPIs’ extended, open surface makes it difficult for small molecules to bind. In order to achieve strong binding, it is frequently necessary to...
| Main Author: | |
|---|---|
| Language: | en_US |
| Published: |
2016
|
| Subjects: | |
| Online Access: | https://hdl.handle.net/2144/14560 |